MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/tp.0000000000004967

Медицинская библиотека · Transplantation · 2024

First-in-human Study With LIS1, a Next-generation Porcine Low Immunogenicity Antilymphocyte Immunoglobulin in Kidney Transplantation.

Viklicky Ondrej, Slatinska Janka, Janousek Libor, Rousse Juliette, Royer Pierre-Joseph, Toutain Pierre-Louis, Cozzi Emanuele, Galli Cesare, Evanno Gwenaelle, Duvaux Odile, Bach Jean-Marie, Soulillou Jean-Paul, Giral Magali, Vanhove Bernard, Blancho Gilles

СтатьяКлиническое исследование I фазыПеревод в очереди

Аннотация

BACKGROUND

Polyclonal rabbit antithymocyte globulins (ATGs) are commonly used in organ transplantation as induction. Anti- N -glycolylneuraminic acid carbohydrate antibodies which develop in response to rabbit carbohydrate antigens might lead to unwanted systemic inflammation. LIS1, the first new generation of antilymphocyte globulins (ALGs) derived from double knockout swine, lacking carbohydrate xenoantigens was already tested in nonhuman primates and rodent models.

METHODS

This open-label, single-site, dose escalation, first-in-human, phase 1 study evaluated the safety, T cell depletion, pharmacokinetics, and pharmacodynamics of LIS1. In an ascending dose cohort (n = 5), a primary kidney transplant recipient at low immunologic risk (panel reactive antibody [PRA] < 20%), received LIS1 for 5 d at either 0.6, 1, 3, 6, or 8 mg/kg. After each patient completed treatment, the data safety monitoring board approved respective dose escalation. In the therapeutic dose cohort (n = 5) in patients with PRA <50% without donor specific antibodies, 2 patients received 8 mg/kg and 3 patients 10 mg/kg.

RESULTS

CD3 + T cell depletion <100/mm 3 at day 2 was observed in all patients who received 6, 8, and 10 mg/kg of LIS1. The terminal half-life of LIS1 was 33.7 d with linearity in its disposition. Lymphocyte repopulation was fast and pretransplant lymphocyte subpopulation counts recovered within 2-4 wk. LIS1 was well tolerated, neither cytokine release syndrome nor severe thrombocytopenia or leukopenia were noticed. Antibodies to LIS1 were not detected.

CONCLUSIONS

In this first-in-human trial, genome-edited swine-derived polyclonal LIS1 ALG was well tolerated, did not elicit antidrug antibodies, and caused time-limited T cell depletion in low- and medium-risk kidney transplant recipients.

Для цитирования: Viklicky Ondrej, Slatinska Janka, Janousek Libor, Rousse Juliette, Royer Pierre-Joseph, Toutain Pierre-Louis, Cozzi Emanuele, Galli Cesare, Evanno Gwenaelle, Duvaux Odile, Bach Jean-Marie, Soulillou Jean-Paul, Giral Magali, Vanhove Bernard, Blancho Gilles. First-in-human Study With LIS1, a Next-generation Porcine Low Immunogenicity Antilymphocyte Immunoglobulin in Kidney Transplantation.. Transplantation. 2024. DOI: 10.1097/tp.0000000000004967.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.